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==========================

Transrectal ultrasound (TRUS) prostate biopsy is extensively used for prostate cancer (PCa) detection and is usually guided by prostate-specific antigen (PSA) screening. Although a confirmatory cutoff for PSA level is currently unavailable for TRUS biopsy,\[[@ref1]\] Thompson *et al*.\[[@ref2]\] reported in a PCa Prevention Trial that the detection rate was 47.4% for patients with PSA levels \>4.0 μg/L, and 27.9% for patients with PSA levels at 2.1--4.0 μg/L, indicating that patients with higher PSA level are at higher risk of PCa.

For patients showing negative results for PCa during the first biopsy, second, or even third biopsies are recommended for continued abnormal PSA values or if high-grade prostatic intraepithelial neoplasia is found on the first biopsy. It has been reported that PCa detection rates vary between 10% and 39% on second biopsies.\[[@ref3][@ref4][@ref5]\] A prospective study reported that the PCa detection rates of males with a PSA level 4--10 μg/L were 22%, 10%, and 5%, respectively, for the initial, second, and third biopsies.\[[@ref6]\] That study suggested that second biopsies produced unnecessary morbidity in a population with PSA 4--10 μg/L.

To improve PCa detection rates, several PSA-related parameters have been applied for repeated biopsies, among which free-total PSA ratio (f/t PSA), PSA density (PSAD), and PSA-prostate transitional zone volume ratio are regarded as having better sensitivity and specificity for PSA-guided second biopsy.\[[@ref7]\]

The incidence and mortality of PCa in Chinese males are lower than in a Western population.\[[@ref8]\] PCa detection rate is only 15.9% for Chinese with a PSA level 4--10 μg/L, according to one large-scale study.\[[@ref9]\] Therefore, it may be inappropriate to use guidelines for biopsy in Chinese patients based on cutoffs for PSA and other parameters using data from a Western population. New cutoff values or new parameters are necessary to reduce the number of noncancer biopsies in the Chinese population. In this study, a new parameter named as PSAD variation rate (PSADVR), which indicated the rate of change of PSAD over 6 months, was presented and evaluated on predictability for guiding second biopsies in Chinese patients.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

Patients {#sec2-1}
--------

A total of 251 Chinese male patients with PSA \<10 μg/L and an initial PCa-negative biopsy were included from February 2010 to August 2015 in our hospital. Of these patients, 227 were asked to undergo a second biopsy 6 months later, because their repeat PSA levels were more than 4 μg/L. Twenty-nine patients declined. Patients would be examined and excluded if they took a 5-α-reductase inhibitor for more than 3 months, underwent indwelling catheterization, or had acute prostatitis, which would affect PSA values. Finally, 184 subjects who underwent two biopsies were enrolled in this research to explore the clinical value of PSADVR. Written informed consents following doctor-patient discussion were obtained from all participants, and all procedures were approved by the Medical Ethics Committee of the First Affiliated Hospital of Soochow University. The data for these subjects were collected immediately after their second biopsies and retrieved from the database of our hospital in October 2015.

Prostate-specific antigen measurement and biopsy strategy {#sec2-2}
---------------------------------------------------------

Venous blood for PSA measurement was extracted before biopsies or digital rectal examination (DRE). PSA values were measured using an electrochemiluminescence immunoassay kit (Yuande Bio-Medical Engineering Co., Ltd., Beijing, China) according to the manufacturer\'s instructions, with a normal range of 0--4 μg/L.

The indication for initial biopsy was a PSA level of 4--10 μg/L with f/t PSA ≤0.16, or PSA \<4 μg/L with a palpable prostate nodule on DRE. The indication for a second biopsy was a repeat PSA \>10 μg/L or PSA 4--10 μg/L with f/t PSA ≤0.16, or new prostate nodule(s) palpated by DRE regardless of PSA. 12-core rectal ultrasound-guided biopsies were performed on the initial set, and an extra 1--2 cores were taken if a prostate nodule was found on ultrasonography. On second biopsies, besides the transrectal punctures as the way on initial biopsy, an extra 1--2 cores were taken in the anterior apical region by a transperineal puncture. All biopsies were performed by a single urologist and ultrasound physician in our medical center.

Calculation of parameters {#sec2-3}
-------------------------

PSA values and three diameter measurements by rectal ultrasound were recorded during the initial and second biopsies. The formulas for each parameter are as follows:

Prostate volume (PV, ml) = anteroposterior diameter × superior-inferior diameter × left-right diameter × 0.52;

f/t PSA = free PSA/total PSA;

PSAD = PSA/PV;

PSADVR (%) = (second PSAD -- first PSAD)/first PSAD × 100%.

A negative or zero value for PSADVR indicates no valid change occurred between the two biopsies. The clinical stage of PCa was evaluated by magnetic resonance imaging and DRE.

Statistical analysis {#sec2-4}
--------------------

All data were analyzed using SPSS 17.0 software (IBM, Armonk, NY, USA). Frequency analysis showed that age, PV, PSA, f/t PSA, PSAD, and PSADVR at the second biopsy had an approximately normal distribution. Comparisons of age, PV, PSA, f/t PSA, and PSADVR between the PCa and non-PCa groups were performed using a *t*-test, but comparisons for PSAD values used the Mann--Whitney *U*--test due to the heterogeneity of variance between the groups. Comparisons of PCa detection rate among the PSADVR groups were performed using the Chi-square test. We assessed the discriminatory value of PSA, PSAD, and PSADVR by computing the area under the receiver operating characteristic curve (AUC). Logistic regression analysis was used to estimate the value of parameters for PCa prediction. A value of *P* \< 0.05 (bilateral) was considered statistically significant.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

On the first biopsy, the average age of 184 participants was 65.1 ± 6.0 years, and all of them were more than 50 years old. The average PSA, PV, f/t PSA and PSAD were 6.76 ± 1.50 μg/L, 43.50 ± 12.60 ml, 0.13 ± 0.08, and 0.17 ± 0.05, respectively. On the second biopsy, 22 subjects had a PSA level \>10 μg/L, and the rest had a PSA level 4--10 μg/L with f/t PSA ≤0.16. No new nodules were detected by DRE. PCa was diagnosed in 24 patients (detection rate 13%).

[Table 1](#T1){ref-type="table"} compares PSA and other parameters between the PCa and non-PCa groups. Of these parameters, PSA, PSAD, and PSADVR were greater in the PCa group than in the non-PCa group, with statistical significance. However, age, PV, and f/t PSA showed no significant difference between the groups. The AUC of the receiver operating characteristic curve (ROC) for PSA, PSAD, and PSADVR was 0.702, 0.743, and 0.790, respectively \[[Figure 1](#F1){ref-type="fig"}\]. PSADVR had the largest AUC. The cutoffs of these parameters are presented in [Table 2](#T2){ref-type="table"}. The greatest specificity (0.824) was obtained at PSADVR of 10%.

###### 

Basic characteristics of PCa and non-PCa groups at second biopsy (mean ± SD)

  Parameters    PCa group (*n* = 24)   Non-PCa group (*n* = 160)   *t*      *P*
  ------------- ---------------------- --------------------------- -------- ---------
  Age (years)   66.9 ± 5.6             64.5 ± 6.0                  1.212    0.231
  PSA (ng/ml)   8.39 ± 1.40            7.16 ± 1.77                 3.048    0.003
  PV (ml)       44.4 ± 9.5             48.5 ± 14.9                 −1.122   0.265
  f/t PSA       0.13 ± 0.04            0.11 ± 0.05                 −1.476   0.147
  PSAD          0.20 ± 0.04            0.16 ± 0.06                 −3.526   \<0.001
  PSADVR (%)    14.15 ± 14.05          −1.36 ± 12.28               5.120    \<0.001

PSA: Prostate-specific antigen; PV: Prostate volume; f/t PSA: Free-total PSA ratio; PSAD: PSA density; PSADVR: PSAD variation rate; SD: Standard deviation; PCa: Prostate cancer.

![ROCs of PSA, PSAD, and PSADVR. The AUCs of ROCs of PSA, PSAD, and PSADVR were 0.702, 0.743, and 0.790, respectively. ROC: Receiver operating characteristic curve; PSA: Prostate-specific antigen; PSAD: PSA density; PSADVR: PSA density variation rate; AUC: Areas under the curve.](CMJ-129-1800-g001){#F1}

###### 

Sensitivity and specificity of cutoffs for PSA, PSAD, and PSADVR

  Parameters    Cutoff   Sensitivity   Specificity   PPV     NPV
  ------------- -------- ------------- ------------- ------- -------
  PSA (ng/ml)   8.0      0.583         0.691         0.400   0.824
  PSAD          0.18     0.750         0.676         0.439   0.882
  PSADVR (%)    10       0.667         0.824         0.571   0.875

PSA: Prostate-specific antigen; PSAD: PSA density; PSADVR: PSAD variation rate. PPV: Positive predictive value; NPV: Negative predictive value.

The PCa detection rates of subjects with PSADVR ≤10% and \>10% were 6.5% (8/128) and 28.6% (16/56), respectively. There was a significant increase in PCa detected in subjects with PSADVR \>10% (*P* \< 0.001, *χ*^2^= 148.42).

In multivariate logistic regression analysis, PSADVR was the only parameter that had a significant relationship with PCa at second biopsy, compared with PSA, PSAD, and f/t PSA \[[Table 3](#T3){ref-type="table"}\]. Remarkably, 14 of 24 PCa cases were considered to be mid-to-high-risk cancers according to Gleason scores (\>6) or clinical T stage (\>T2a). PSADVR had a statistically significant positive correlation with PCa risk level (*r* = 0.63, *P* = 0.03, Spearman correlation), but PSA and PSAD did not (*r* = 0.02, *P* = 0.945; *r* = 0.27, *P* = 0.393, respectively). Of 16 PCa cases with PSADVR \>10%, 12 were mid-to-high-risk cancers. However, only two cancers with PSADV ≤10% were mid-to-high-risk (PSADVR = 3%, T1N0M0, Gleason score = 7; PSADVR \<0, T2aN0M0, Gleason score = 8).

###### 

Multivariate *OR*s and 95% *CI*s for PSA, PSAD, and PSADVR for PCa detection at second biopsy by logistic regression analysis

  Parameters   *OR*    95% *CI* of *OR*   *P*
  ------------ ------- ------------------ -------
  PSA          1.118   0.632--1.978       0.678
  PSAD         1.052   0.902--1.228       0.517
  f/t PSA      1.066   0.856--1.326       0.570
  PSADVR       2.480   1.131--5.438       0.023

PSA: Prostate-specific antigen; f/t PSA: Free-total PSA ratio; PSAD: PSA density; PSADVR: PSAD variation rate; *CI*: Confidential intervals; *OR*s: Odds ratios; PCa: Prostate cancer.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

PSA and related parameters have been widely used for PCa screening and detection. A missed diagnosis of PCa in a biopsy is to some extent unavoidable, because of the multifocal characteristics of PCa and the limitations of prostate biopsies due to sample collection, which can only sample a small part of the entire prostate.\[[@ref10]\] However, biopsy remains the most effective clinical method for PCa detection.

Despite tremendous efforts and progress in using PSA cutoffs in guiding prostate biopsy, the benefits remain questionable, and the results of meta-analyses are controversial or inconsistent.\[[@ref11]\] Although the current PSA cutoff helps urologists detect and diagnose PCa in millions of patients annually, a much greater number of males who underwent biopsies have shown no cancer, and thus suffered from economic loss and trauma.\[[@ref12]\] In addition, there has been no significant reduction in the mortality from PCa since the introduction of PSA screening.\[[@ref13]\]

The necessity for a second biopsy should be carefully evaluated in clinical practice because the detection rate of PCa in a second biopsy proved to be much lower than that in the initial biopsy.\[[@ref5]\] Repeat biopsy is considered acceptable when serum PSA is higher than 10 μg/L. However, when PSA levels are 4--10 μg/L, repeat biopsy is controversial, because most results are noncancers or low-risk cancers. Moreover, the invasiveness of a repeat TRUS biopsy is not accepted by some subjects. About 15% of recruits in this research refused the second biopsy, complaining of severe pain. Obviously, a new parameter with better sensitivity and specificity for use in guiding second biopsies is greatly needed.

PSA-related parameters, such as f/t PSA and PSAD, reportedly improved the sensitivity and specificity of PSA for guiding the second biopsy. Djavan *et al*.\[[@ref7]\] reported a study of 820 participants with PSA 4--10 μg/L, in which patients diagnosed with benign prostatic hyperplasia (BPH) in the initial biopsy underwent a repeat biopsy 6 weeks later. The authors reported that f/t PSA provided a sensitivity of 90% and a specificity of 50% at a cutoff of 0.30, and PSAD had a sensitivity of 74% and a specificity of 44% at a cutoff of 0.13 (when compared to PSA alone, with sensitivity of 80% and specificity of 38% at a cutoff of 5.5 μg/L). However, in our research, the mean values of f/t PSA in the PCa and non-PCa groups showed no significant difference, and f/t PSA showed no significance in logistic regression analysis. The result was contrary to Djavan\'s study. One possible reason was that the number of PCa patients was much less than those with BPH; another reason was that the levels of some PSAs in the PCa group were higher than 10 μg/L. In the literature, although PSA velocity (PSAV) is statistically associated with outcomes of definite PCa in first or repeat prostate biopsies,\[[@ref5][@ref14][@ref15]\] it adds little extra value to PSA itself for PCa detection.\[[@ref16][@ref17]\]

On the other hand, optimization of methods may also provide benefits for detection rate in repeat biopsies. One of the potential improvements is to increase the number of cores in a large prostate. Eskew *et al*.\[[@ref18]\] reported that 12--15 core biopsies in prostates larger than 50 ml showed a detection rate 35% greater for PCa compared with a 6-core biopsy. Another extreme example was saturation biopsy. A high incidence of PCa (41%) has reportedly been detected by saturation biopsies in subjects who had at least two previously negative, 8-core biopsy sessions.\[[@ref19]\] In addition, the anterior apex of the prostate is an area that can be easily missed in a regular transrectal 12-core biopsy. Although most PCa is located in the lateral peripheral zone of the prostate, it was reported that about 17% of cancers were detected by apical region biopsy.\[[@ref20]\] In this study, extra anterior apical cores were performed on all subjects on second biopsies, and three cancers (12.5%) were detected in this region, with Gleason scores of 6, 6, and 7, respectively.

In this study, we designed a new concept of PSADVR to describe the changes in PSAD over 6 months. Compared with static parameters such as PSA, f/t PSA, and PSAD, PSADVR described not only dynamic changes in PSA but also the relationship between PSA and PV. It dramatically demonstrated predictive value in second biopsies performed at a relatively long interval from the initial biopsy.

Theoretically, PSAD should remain constant in males with a benign prostate for a period. In 20 male outpatients under 50 years old without prostatitis or any lower urinary tract symptoms, PSAD varied between individuals but remained constant over 1--3 years. All PSADVR values in these 20 males were \<3%. In non-PCa, an increase in PSA was mostly caused by an increase in PV. However, in PCa, PSAD significantly increases along with disease progression, because prostate glandular epithelium invasion causes a large amount of PSA release into the blood. Therefore, we predict that PSADVR will be an excellent parameter for PCa detection, especially for clinically significant cancers. In this study, PSADVR had more specificity than PSA and PSAD, and a significant increase in PCa detection rate was observed in males with PSADVR \>10%. Moreover, PSADVR was the only independent factor that aided PCa detection in a second biopsy compared to PSA, PSAD, and f/t PSA.

Chan *et al*.\[[@ref21]\] reported that although biopsies of 9 or more cores could detect earlier stage cancers than those with 8 cores or less, no differences were noted between initial biopsy and repeat biopsy cancer groups in Gleason scores, organ confinement, or extracapsular invasion.\[[@ref6]\] Thus, it is still questionable whether second biopsies would help increase the proportion of detection of indolent cancers. In this research, PSADVR was positively correlated with mid-to-high-risk cancers (Gleason score \>6 or clinical stage \>T2a), and most PCa patients with PSADVR \>10% were mid-to-high-risk cancers. Therefore, the new parameter might help identify PCa requiring timely intervention.

We strongly recommended that the time interval between two biopsies should be more than 3 months when calculating PSADVR, based on the calculation method for PSAV,\[[@ref22][@ref23]\] since a shorter interval may cause statistical confusion. Thus, PSADVR is mostly appropriate for patients who undergo second biopsies 3 months or more after the first biopsy.

A limitation is the small number of participants in this study, which might affect the accuracy of the conclusions. In addition, the average PVs of PCa and non-PCa groups were both larger than 40 ml, which meant the conclusion was drawn from a prostatic hyperplasia population. Whether PSADVR is practical in small prostate patients' needs further study. Another limitation of the current study was that not all patients underwent radical prostatectomy; it was reported that there was a remarkable difference between clinical stage and postoperatic pathologic stage.\[[@ref24]\] Therefore, the relation of PSADVR and pathological stages were not confirmed.

In conclusion, PSADVR could serve as a new PSA-related parameter with a valuable clinical impact; PSADVR has better sensitivity and specificity for PCa detection, and avoids many negative biopsies. It also has satisfactory predictive value for mid-to-high-risk cancers requiring prompt treatment. However, prospective and multicenter researches with large sample size should be conducted to confirm the PCa predictability of PSADVR on second biopsy.
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